| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/0014-2999(86)90333-X |
| P698 | PubMed publication ID | 3021478 |
| P50 | author | Gavril W. Pasternak | Q92217073 |
| P2093 | author name string | Simantov R | |
| Clark JA | |||
| Ling GS | |||
| P433 | issue | 1-2 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 33-38 | |
| P577 | publication date | 1986-09-01 | |
| P1433 | published in | European Journal of Pharmacology | Q1376712 |
| P1476 | title | Naloxonazine actions in vivo | |
| P478 | volume | 129 |
| Q34169931 | 14-Methoxymetopon, a very potent mu-opioid receptor-selective analgesic with an unusual pharmacological profile |
| Q28572514 | A naloxonazine sensitive (mu1 receptor) mechanism in the parabrachial nucleus modulates eating |
| Q28479211 | A screen against Leishmania intracellular amastigotes: comparison to a promastigote screen and identification of a host cell-specific hit |
| Q48536754 | Actions of opioids on respiratory activity via activation of brainstem mu-, delta- and kappa-receptors; an in vitro study |
| Q44352022 | Activation of opioid mu-receptor by loperamide to lower plasma glucose in streptozotocin-induced diabetic rats |
| Q34482188 | Activation of the opioid μ1, but not δ or κ, receptors is required for nicotine reinforcement in a rat model of drug self-administration |
| Q44332868 | Activity at phencyclidine and mu opioid sites mediates the hyperalgesic and antinociceptive properties of the N-terminus of substance P in a model of visceral pain |
| Q44344629 | Analgesic effects of Tyr-W-MIF-1: a mixed mu2-opioid receptor agonist/mu1-opioid receptor antagonist |
| Q35981158 | Analgesic tolerance to microinjection of the micro-opioid agonist DAMGO into the ventrolateral periaqueductal gray |
| Q48579779 | Antinociceptive action of botulinum toxin type A in carrageenan-induced mirror pain. |
| Q44345988 | Antinociceptive effect of buprenorphine in mu1-opioid receptor deficient CXBK mice |
| Q44352909 | Antinociceptive properties of FR140423 mediated through spinal delta-, but not mu- and kappa-, opioid receptors |
| Q44348395 | Central effect of SNC 80, a selective and systemically active delta-opioid receptor agonist, on gastrointestinal propulsion in the mouse |
| Q44336158 | Comparison of naloxonazine and β-funaltrexamine antagonism of μ1 and μ2 opioid actions |
| Q44347475 | Conditioned immunomodulation: investigations of the role of endogenous activity at mu, kappa, and delta opioid receptor subtypes |
| Q44351810 | Contribution of spinal mu1-opioid receptors to morphine-induced antinociception |
| Q37170275 | Development of delta opioid peptides as nonaddicting analgesics |
| Q73081577 | Differential antagonism of endomorphin-1 and endomorphin-2 spinal antinociception by naloxonazine and 3-methoxynaltrexone |
| Q44041751 | Differential antagonism of endomorphin-1 and endomorphin-2 supraspinal antinociception by naloxonazine and 3-methylnaltrexone |
| Q43745077 | Differential antinociceptive effects induced by intrathecally administered endomorphin-1 and endomorphin-2 in the mouse |
| Q44352199 | Differential involvement of mu-opioid receptor subtypes in endomorphin-1- and -2-induced antinociception |
| Q44345097 | Differential sensitivity of opioid-induced feeding to naloxone and naloxonazine |
| Q44340845 | Dopamine depletion augments endogenous opioid-induced locomotion in the nucleus accumbens using both mu 1 and delta opioid receptors |
| Q44348633 | Effect of the blockade of mu1-opioid and 5HT2A-serotonergic/alpha1-noradrenergic receptors on sweet-substance-induced analgesia |
| Q73865949 | Endogenous opiates in the chick retina and their role in form-deprivation myopia |
| Q42175351 | Endomorphin analogues containing D-Pro2 discriminate different mu-opioid receptor mediated antinociception in mice |
| Q44342424 | Endomorphin-1, an endogenous mu-opioid receptor agonist, improves apomorphine-induced impairment of prepulse inhibition in mice |
| Q35873168 | Interaction between the mu-agonist dermorphin and the delta-agonist [D-Ala2, Glu4]deltorphin in supraspinal antinociception and delta-opioid receptor binding |
| Q43865401 | Involvement of mu(1)-opioid receptors and cholinergic neurotransmission in the endomorphins-induced impairment of passive avoidance learning in mice |
| Q44352183 | Involvement of opioid mu1-receptors in opioid-induced acceleration of striatal and limbic dopaminergic transmission |
| Q44225608 | Mechanisms involved in morphine-induced activation of synaptosomal Na+,K+-ATPase |
| Q44341747 | Micro1-opioid antagonist naloxonazine alters ethanol discrimination and consumption |
| Q52191417 | Modification of morphine-induced place preference by diabetes. |
| Q43706636 | Modulation of breathing by mu1 and mu2 opioid receptor stimulation in neonatal and adult rats |
| Q34795487 | Mu (mu) opioid receptor regulation of ethanol-induced dopamine response in the ventral striatum: evidence of genotype specific sexual dimorphic epistasis. |
| Q33581970 | Mu opioid receptors in pain management |
| Q37236111 | Mu opioids and their receptors: evolution of a concept |
| Q33978499 | Opioid-receptor-heteromer-specific trafficking and pharmacology |
| Q34437456 | Opioids and their receptors: Are we there yet? |
| Q34125112 | Pharmacologic characterization in the rat of a potent analgesic lacking respiratory depression, IBNtxA. |
| Q38300930 | Pharmacological characterization of the dermorphin analog [Dmt(1)]DALDA, a highly potent and selective mu-opioid peptide |
| Q34792671 | Production of antinociception by peripheral administration of [Lys7]dermorphin, a naturally occurring peptide with high affinity for mu-opioid receptors |
| Q36064141 | Pronociceptive and Antinociceptive Effects of Buprenorphine in the Spinal Cord Dorsal Horn Cover a Dose Range of Four Orders of Magnitude |
| Q69848797 | Quantitative autoradiographic distribution of meptazinol-sensitive binding sites in rat brain |
| Q43562051 | Receptor binding and biological activity of the dermorphin analog Tyr-D-Arg(2)-Phe-Sar (TAPS). |
| Q38346695 | Reduced expression of a novel mu-opioid receptor (MOR) subtype MOR-1B in CXBK mice: implications of MOR-1B in the expression of MOR-mediated responses |
| Q28378301 | Selective antagonism by naloxonazine of antinociception by Tyr-D-Arg-Phe-beta-Ala, a novel dermorphin analogue with high affinity at mu-opioid receptors |
| Q35193713 | Stress-induced activation of ventral tegmental mu-opioid receptors reduces accumbens dopamine tone by enhancing dopamine transmission in the medial pre-frontal cortex. |
| Q34333349 | The pharmacology of mu analgesics: from patients to genes |
| Q67486592 | The role of mu1 receptor in physical dependence on morphine using the mu receptor deficient CXBK mouse |
| Q44350750 | The role of opioid receptor subtypes in the development of behavioral sensitization to ethanol |
| Q41872646 | Unexpected prosecretory action component of loperamide at mu-opioid receptors in the guinea-pig colonic mucosa in vitro |
| Q36641338 | mu opiate receptor: cDNA cloning and expression |
| Q44339252 | µ1 -Opioid receptors in the dorsomedial and ventrolateral columns of the periaqueductal grey matter are critical for the enhancement of post-ictal antinociception |
Search more.